Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Estradiol Levels and Lung Cancer Outcomes
Author
Howard (Jack) West, MD

This work is still early, but it's been interesting to see a lab-based correlate emerge along with with the observation of women, and particularly older women, doing better in lung cancer studies (several prior posts here). Last year, the folks at Cell Therapeutics, Inc., analyzed results from their trials with Xyotax (post here), which demonstrated that their favorable results were seen in younger women. Estrogen may be very relevant to several biological processes related to lung cancer (reviewed in this post), so there is reason to believe that sex differences in lung cancer outcomes are plausible.

Results at ASCO this year were notable for a couple of presentations that noted a correlation of estradiol levels with lung cancer outcomes. Estradiol is the major form of estrogen in humans, the "female" hormone, although levels are present in men as well. The results for women under 60 vs. 60 and older in a couple of xyotax trials were broken down by estradiol levels. Women with lower estradiol levels did better regardless of their age, while those with higher estradiol levels did less well, again regardless of their age:

estradiol and age in women (Click to enlarge)

So age appears to be more of a surrogate for hormonal status than an independent prognostic factor, at least according to an early analysis.

It would be interesting, though, to see if estradiol levels were also prognostic in men, since men also have detectable levels. In fact, that was looked at in the Xyotax trials, and would you believe that the men with lower estradiol levels (below the median) had a significantly longer survival than the men with higher estradiol levels? Here's the figure for the results, among 318 of 583 men on the STELLAR-3 (carbo/taxol vs. carbo/xyotax) or STELLAR-4 trial (gemcitabine or navelbine vs. xyotax) who had serum samples available:

estradiol in men Note: Estradiol levels are measured differently than in the above curve in women, hence the different numbers (scale).

Unlike women on these xyotax trials, men didn't do better with xyotax regardless of their estradiol levels.

There are trials that are just now beginning to look into using anti-estrogen therapies like tamoxifen or faslodex (fulvestrant) in combination with tarceva or other anti-cancer strategies, to see whether they will confer the survival benefit that seems to be present for post-menopausal women to pre-menopausal women, or maybe even men. Right now, we haven't seen the results of these trials, but I'll be watching for more and will keep everyone posted if we learn more.

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancers OncTalk 2024
Video
  This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University Topics include: - Myeloma 101: Facts and Fiction of the 'Myeloma Marathon' - Updates in DLBCL - Treatment Basics of Bone Marrow Transplant - Frontline Therapies in Myelofibrosis - Panel Discussions and a Question-and-Answer session
Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.

Forum Discussions

Hi Stan,

It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving.  I know it meant a...

Hi Stan!  It is good to hear from you -- I am so very happy you are doing well.  I agree with Janine that family and friends - our chosen family...

Recent Comments

JOIN THE CONVERSATION
Hey Bluebird,

I understand…
By JanineT GRACE … on
So good to hear from you Stan
By dbrock on
Hi Stan,

It's so good to…
By JanineT GRACE … on